Colorectal liver metastases: A critical review of state of the art

Liver Cancer

Volumn 6, Issue 1, 2017, Pages 66-71

  Jones, Robert P ^a,b   Kokudo, Norihiro ^c   Folprecht, Gunnar ^d   Mise, Yoshihiro ^c   Unnoe, Michiaki ^e   Malik, Hassan Z ^b   Fenwick, Stephen W ^b   Poston, Graeme J ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Liver cancer; Surgery

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; TUMOR MARKER;

CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL LIVER METASTASIS; CONFERENCE PAPER; DECISION MAKING; EVIDENCE BASED PRACTICE; HUMAN; LONG TERM SURVIVAL; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PALLIATIVE THERAPY; PATIENT ASSESSMENT; PERIOPERATIVE PERIOD; PROGRESSION FREE SURVIVAL; REPEAT PROCEDURE; RISK FACTOR; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 85020891168     PISSN: 22351795     EISSN: 16645553     Source Type: Journal    
DOI: 10.1159/000449348     Document Type: Conference Paper

References (27)

1. Jones RP, Hamann S, Malik HZ, Fenwick SW, Poston GJ, Folprecht G: Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer. Eur J Cancer 2014;50:1590-1601
2. Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier P, Rubbia-Brandt L, Sobrero A, Tabernero J, Teh C, Van Cutsem E, Jean-Nicolas Vauthey of the EGOSLIM (Expert Group on OncoSurgery management of LIver Metastases) group: The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 2012;17:1225-1239
3. Shindoh J, Loyer EM, Kopetz S, Boonsirikamchai P, Maru DM, Chun YS, Zimmitti G, Curley SA, Charnsangavej C, Aloia TA, Vauthey JN: Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol 2012;30:4566-4572
4. Jones RP, Stättner S, Dunne DF, O'Grady E, Smethurst A, Terlizzo M, Malik HZ, Fenwick SW, Poston GJ: Radiological assessment of response to neoadjuvant transcatheter hepatic therapy with irinotecan-eluting beads (DEBIRI® ) for colorectal liver metastases does not predict tumour destruction or long-term outcome. Eur J Surg Oncol 2013;39:1122-1128
5. Jones RP, Jackson R, Dunne DF, Malik HZ, Fenwick SW, Poston GJ, Ghaneh P: Systematic review and metaanalysis of follow-up after hepatectomy for colorectal liver metastases. Br J Surg 2012;99:477-486
6. Kokudo N, Tada K, Seki M, Ohta H, Azekura K, Ueno M, Matsubara T, Takahashi T, Nakajima T, Muto T: Anatomical major resection versus nonanatomical limited resection for liver metastases from colorectal carcinoma. Am J Surg 2001;181:153-159
7. Mise Y, Aloia TA, Brudvik KW, Schwarz L, Vauthey JN, Conrad C: Parenchymal-sparing Hepatectomy in Colorectal Liver Metastasis Improves Salvageability and Survival. Ann Surg 2016;263:146-152
8. Torzilli G, Procopio F, Botea F, Marconi M, Del Fabbro D, Donadon M, Palmisano A, Spinelli A, Montorsi M: One-stage ultrasonographically guided hepatectomy for multiple bilobar colorectal metastases: a feasible and effective alternative to the 2-stage approach. Surgery 2009;146:60-71
9. Kingham TP, Correa-Gallego C, D'Angelica MI, Gönen M, DeMatteo RP, Fong Y, Allen PJ, Blumgart LH, Jarnagin WR: Hepatic parenchymal preservation surgery: decreasing morbidity and mortality rates in 4,152 resections for malignancy. J Am Coll Surg 2015;220:471-479
10. Stättner S, Jones RP, Yip VS, Buchanan K, Poston GJ, Malik HZ, Fenwick SW: Microwave ablation with or without resection for colorectal liver metastases. Eur J Surg Oncol 2013;39:844-849
11. Tanis E, Nordlinger B, Mauer M, Sorbye H, van Coevorden F, Gruenberger T, Schlag PM, Punt CJ, Ledermann J, Ruers TJ: Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. Eur J Cancer 2014;50:912-919
12. Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, Nitti D, Torri V, Elias D, O'Callaghan C, Langer B, Martignoni G, Bouché O, Lazorthes F, Van Cutsem E, Bedenne L, Moore MJ, Rougier P: Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008;26:4906-4911
13. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T, EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK, Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), Australasian Gastro-Intestinal Trials Group (AGITG), Fédération Francophone de Cancérologie Digestive (FFCD): Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371:1007-1016
14. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van Cutsem E, Scheithauer W, Gruenberger T, EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK, Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), Australasian Gastro-Intestinal Trials Group (AGITG), Fédération Francophone de Cancérologie Digestive (FFCD): Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013;14:1208-1215
15. Sorbye H, Mauer M, Gruenberger T, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Van Cutsem E, Scheithauer W, Lutz MP, Nordlinger B, EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK (CRUK), Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), Australasian Gastro-Intestinal Trials Group (AGITG), Fédération Francophone de Cancérologie Digestive (FFCD): Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983) [EORTC Intergroup Trial 40983]. Ann Surg 2012;255:534-539
16. Jones RP, Malik HZ, Fenwick SW, Poston GJ: Perioperative chemotherapy for resectable colorectal liver metastases: where now? Eur J Surg Oncol 2013;39:807-811
17. Ychou M, Hohenberger W, Thezenas S, Navarro M, Maurel J, Bokemeyer C, Shacham-Shmueli E, Rivera F, Kwok-Keung Choi C, Santoro A: A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 2009;20:1964-1970
18. Primrose J, Falk S, Finch-Jones M, Valle J, O'Reilly D, Siriwardena A, Hornbuckle J, Peterson M, Rees M, Iveson T, Hickish T, Butler R, Stanton L, Dixon E, Little L, Bowers M, Pugh S, Garden OJ, Cunningham D, Maughan T, Bridgewater J: Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 2014;15:601-611
19. Nordlinger B, Poston GJ, Goldberg RM: Should the Results of the New EPOC Trial Change Practice in the Management of Patients With Resectable Metastatic Colorectal Cancer Confined to the Liver? J Clin. Oncol 2015;33:241-243
20. Tanaka K, Shimada H, Matsuo K, Nagano Y, Endo I, Sekido H, Togo S: Outcome after simultaneous colorectal and hepatic resection for colorectal cancer with synchronous metastases. Surgery 2004;136:650-659
21. Adam R, Bhangui P, Poston G, Mirza D, Nuzzo G, Barroso E, Ijzermans J, Hubert C, Ruers T, Capussotti L, Ouellet JF, Laurent C, Cugat E, Colombo PE, Milicevic M: Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg 2010 Nov;252:774-787
22. Poston GJ, Adam R, Alberts S, Curley S, Figueras J, Haller D, Kunstlinger F, Mentha G, Nordlinger B, Patt Y, Primrose J, Roh M, Rougier P, Ruers T, Schmoll HJ, Valls C, Vauthey NJ, Cornelis M, Kahan JP: Onco Surge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 2005;23:7125-7134
23. Dunne DF, Jones RP, Lythgoe DT, Pilkington FJ, Palmer DH, Malik HZ, Poston GJ, Lacasia C, Jack S, Fenwick SW: Cardiopulmonary exercise testing before liver surgery. J Surg Oncol 2014;110:439-444
24. Jones RP, Vauthey JN, Adam R, Rees M, Berry D, Jackson R, Grimes N, Fenwick SW, Poston GJ, Malik HZ: Effect of specialist decision-making on treatment strategies for colorectal liver metastases. Br J Surg 2012;99:1263-1269
25. Morris EJ, Forman D, Thomas JD, Quirke P, Taylor EF, Fairley L, Cottier B, Poston G: Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg 2010;97:1110-1118
26. Ruers T, Punt C, Van Coevorden F, Pierie JP, Borel-Rinkes I, Ledermann JA, Poston G, Bechstein W, Lentz MA, Mauer M, Van Cutsem E, Lutz MP, Nordlinger B, EORTC Gastro-Intestinal Tract Cancer Group, Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO) and the National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG): Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004) [EORTC 40004]. Ann Oncol 2012;23:2619-2626
27. Ruers T, Punt CJ, van Coevorden F, Pierie JP, Rinkes IB, Ledermann J, et al: O-018 Radiofrequency ablation [RFA] combined with chemotherapy for unresectable colorectal liver metastases [CRC LM]: Longterm survival results of a randomised phase II study of the EORTC-NCRI CCSG-ALM Intergroup is 40004 [CLOCC]. Ann Oncol 2015;26(suppl 4):iv114-iv5